Clinical outcomes of eradication of Helicobacter pylori in nonulcer dyspepsia in a population with a high prevalence of infection : Results of a 12-month randomized, double blind, placebo-controlled study

• Published in: Digestive diseases and sciences Vol. 51; no. 1; pp. 89 - 98
• Main Authors: MAZZOLENI, Luiz E, SANDER, Guilherme B, CARTELL, André, EDELWEISS, Maria I. A, UCHOA, Diego M, PROLLA, Joao C, OTT, Eduardo A, BARROS, Sérgio G. S, FRANCESCONI, Carlos F, POLANCZYK, Carisi A, WORTMANN, André C, THEIL, Alexandro L, FRITSCHER, Leandro G, RIVERO, Luis F
• Format: Journal Article
• Language: English
• Published: Heidelberg Springer 2006; Springer Nature B.V
• Subjects: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin - therapeutic use; Anti-Infective Agents - therapeutic use; Bacterial diseases; Bacterial diseases of the digestive system and abdomen; Biological and medical sciences; Biopsy; Brazil - epidemiology; Clarithromycin - therapeutic use; Double-Blind Method; Drug Therapy, Combination; Dyspepsia - drug therapy; Dyspepsia - etiology; Dyspepsia - pathology; Endoscopy, Gastrointestinal; Feeding. Feeding behavior; Female; Follow-Up Studies; Fundamental and applied biological sciences. Psychology; Gastric Mucosa - microbiology; Gastric Mucosa - pathology; Gastritis - complications; Gastritis - drug therapy; Gastritis - microbiology; Gastroenterology. Liver. Pancreas. Abdomen; Helicobacter Infections - drug therapy; Helicobacter Infections - epidemiology; Helicobacter Infections - microbiology; Helicobacter pylori; Helicobacter pylori - isolation & purification; Human bacterial diseases; Humans; Infectious diseases; Lansoprazole; Male; Medical sciences; Middle Aged; Omeprazole - analogs & derivatives; Omeprazole - therapeutic use; Other diseases. Semiology; Prevalence; Prospective Studies; Proton Pump Inhibitors; Stomach. Duodenum. Small intestine. Colon. Rectum. Anus; Treatment Outcome; Vertebrates: anatomy and physiology, studies on body, several organs or systems; Brazil; Helicohacter pylori; Prognosis; Prevalence; Spirillales; Dyspepsia; Spirillaceae; Metabolic diseases; Eradication; Gastrointestinal; Epidemiology; Gastritis; Infection; Helicobacter pylori; Gastroenterology; Double blind study; Digestive diseases; Bacteria; Endoscopy; Gastric disease
• ISSN: 0163-2116; 1573-2568
• DOI: 10.1007/s10620-006-3090-6

Ninety-one Helicobacter pylori-positive patients with nonulcer dyspepsia were randomized to receive either lansoprazole, amoxicillin, and clarithromycin or lansoprazole and placebo. A validated questionnaire assessed dyspeptic symptoms at baseline and at 3, 6, and 12 months. Endoscopies and biopsies were performed at baseline and at 3 and 12 months. There was an overall trend, although not statistically significant, for a benefit of H. pylori eradication. Of the patients in the antibiotics group, 16 of 46 (35%) had symptomatic improvement, versus 9 of 43 (21%) in the control group (P = 0.164). In a secondary analysis, it was found that of the patients without endoscopic gastric erosions, 15 of 34 (44%) in the antibiotics group and 5 of 33 (15%) of controls had symptomatic improvement (P = 0.015). Helicobacter pylori eradication did not prove to be clinically beneficial, although a tendency to symptomatic benefit was detected. Further studies are necessary to confirm the implications of endoscopic gastric erosions in these patients.